Indications
Lifitegrast ophthalmic solution is used to treat the signs and symptoms of dry eye disease (DED).
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Lifitegrast binds to LFA-1, an integrin, which is a cell surface protein found on leukocytes. By binding there, it blocks LFA-1 from interacting with its cognate ligand, intercellular adhesion molecule-1 (ICAM-1). In DED, ICAM-1 may be overexpressed in corneal and conjunctival tissues. The LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse, and this results in T-cell activation and migration to target tissues.
In vitro studies showed that lifitegrast may inhibit Tcell adhesion to ICAM-1 in a human T-cell line. It may also inhibit secretion of inflammatory cytokines in human peripheral blood mononuclear cells. The exact mechanism of action of lifitegrast in DED is not known.
Pregnancy & Breastfeeding
We don't have any data on the use of Lifitegrast in pregnant women, so it isn't known whether the medicine carries any risk in pregnancy. Nothing is known either about whether Lifitegrast passes into human milk, what effect it might have on a breastfed infant, or whether it changes milk production.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.